Is TrenibotulinumtoxinE FDA Approved in the United States?

By Dr. Iryna Lazuk, MD — Physician-led perspective from Lazuk Esthetics in Alpharetta, Georgia.
Direct answer: No. TrenibotulinumtoxinE was not FDA approved in the United States after AbbVie received an April 2026 complete response letter requesting more manufacturing information. The company said the letter did not request additional clinical studies or identify a safety or efficacy concern. In the European Union, the product is authorized as Boey for occasional treatment of qualifying glabellar lines under prescription.
A product can be authorized in Europe and still remain unavailable as an approved U.S. treatment.
What does the FDA letter mean?
A complete response letter means the application was not ready for approval in its current form. It is not permission to import, compound, relabel, or use the European product as if the U.S. review were complete.
What is approved in Europe?
EMA authorized Boey for adults with moderate-to-severe glabellar lines with important psychological impact. It is prescription-only and physician-administered.
What is the practical next step?
If you are interested in a short-duration toxin, ask which products are currently FDA approved for the proposed indication and whether waiting for a U.S. decision is the safer choice.
I would bring the exact product, proposed protocol, medication list, and goal to a qualified clinician rather than trying to translate a trend into a treatment alone.
When should I seek medical care?
Seek urgent care for difficulty breathing, swallowing, speaking, severe weakness, or other possible toxin-spread symptoms after any botulinum toxin injection.
Urgent breathing, swallowing, neurologic, eye, or rapidly progressive symptoms require prompt medical evaluation rather than online troubleshooting.
Frequently asked questions
Can a U.S. clinic import Boey for cosmetic use?
European authorization does not create U.S. approval; product sourcing and use must comply with U.S. law and regulation.
Did FDA reject it for safety?
AbbVie stated the complete response letter concerned manufacturing information and requested no new clinical studies.
Could FDA approve it later?
The sponsor can respond to the agency, but timing and outcome should not be assumed.
Follow Dr. Lazuk
Dr. Iryna Lazuk is the physician co-founder of Lazuk Esthetics and Dr. Lazuk Cosmetics. I evaluate anatomy, skin behavior, health context, goals, evidence, timing, maintenance burden, and whether waiting is the better intervention.
Contact
Lazuk Esthetics | 4380 Kimball Bridge Rd, Alpharetta, GA 30022 | Concierge Service: (770) 744-3146
Medical disclaimer
This article is educational and does not diagnose a condition or establish treatment candidacy. Medication and procedure decisions require individualized evaluation by an appropriately qualified clinician.


Comments